Long subcutaneous tunnelling reduces infection rates in paediatric external ventricular drains

Christian D. E. Collins · John C. Hartley · Aabir Chakraborty · Dominic N. P. Thompson

Abstract

Purpose The aim of this study is to report the efficacy of long subcutaneous tunnelling of external ventricular drains in reducing rates of infection and catheter displacement in a paediatric population.

Methods In children requiring external ventricular drainage, a long-tunnelled drain was placed and managed according to a locally agreed guideline. End points were novel CSF infection incurred during the time of drainage and re-operation to re-site displaced catheters. Data were compared to other published series.

Results One hundred eighty-one long-tunnelled external ventricular drains (LTEVDs) were inserted. The mean age was 6.6 years (range 0–15.5 years). Reasons for insertion included intraventricular haemorrhage (47 %), infection (27 %), tumour-related hydrocephalus (7.2 %), as a temporising measure (17 %) and trauma (2.2 %). The overall new infection rate for LTEVD was 2.76 %. If the 48 cases where LTEVDs were inserted to treat an existing infection are excluded, the infection rate was 3.8 % (5/133). The mean duration of insertion was 10 days (range 0–42 days). Four LTEVDs (2.2 %) were inadvertently dislodged, requiring reinsertion. Thirteen patients required removal of EVD alone.

There was a significant difference ($p < 0.05$) when comparing our infection rate to 14 publications of infection rates in short-tunnelled EVDs; however, there was no difference when comparing our data to three publications using LTEVDs. Conclusion The use of an antibiotic-impregnated LTEVD, managed according to a predefined guideline, is associated with significantly reduced infection and displacement rates when compared with contemporary series. It is suggested that this reduction is of both clinical and economic benefits.

Keywords EVD · Ventricular drain · Infection · Hydrocephalus · Tunelled · Ventriculostomy

Introduction

Insertion of external ventricular drains (EVDs) is one of the most common neurosurgical procedures performed in neurosurgery today, with over 20,000 EVDs inserted annually in the USA alone [1]. The most widely practised surgical technique for insertion of EVDs involves the insertion of a ventricular catheter into the ventricle with tunnelling of the distal end a short distance away from the incision, a short-tunnelled EVD.

The complication rate from short-tunnelled EVDs is high and includes infection, CSF leak, blockage, misplacement of the ventricular catheter at the time of surgery and the inadvertent migration of the ventricular catheter following surgery [2]. The overall complication rate ranges from 3.4 to 32.2 % [2–8]. The presumed mechanism of infection is bacterial entry at the exit site on the skin with subsequent ascending colonisation of the catheter. There are data suggesting that increasing the distance from the EVD exit site to the burr hole reduces infection [9–11].
We therefore hypothesised that insertion of a long-tunnelled EVD (LTEVD) would reduce the rate of novel infection and, since LTEVDs require the incorporation of a reservoir, would also reduce the rate of inadvertent migration of the catheter out of the ventricle.

We have defined a LTEVD as a ventricular access device comprising a ventricular catheter, a reservoir and a distal catheter that is externalised at the level of the abdomen or anterior chest wall. This paper is a retrospective audit of LTEVD insertions at a single paediatric neurosurgical institution, specifically addressing infection and mechanical complications.

Methods

A retrospective review was conducted in all the patients who had a LTEVD inserted from 2 January 2008 to 9 March 2012. The policy of the neurosurgical department throughout the course of this study was to insert all EVDs in the operating theatre.

Protocol

A local guideline for insertion of LTEVDs was in place for the duration of this study. This comprised antibiotic prophylaxis (flucloxacillin and amikacin) at induction of anaesthesia and for a further period of 24 h, clipping of hair at least 2 cm away from the wound and preparation of the field with povidone iodine solution and/or chlorhexidine (0.5 % in 70 % alcohol).

Bactiseal™ antibiotic-impregnated ventricular and peritoneal catheters were connected to a Miethke™ ventricular access device. Subcutaneous tunnelling was performed from the cranial wound to the chest wall or abdomen, allowing the distal catheter to be passed. A purse-string suture was applied to the exit site and covered with a waterproof dressing. The peritoneal catheter was not cut, allowing a long length of catheter to extend beyond the exit site.

Post-operatively, surgical and nursing staff followed the external ventricular drain clinical guideline of Great Ormond Street Hospital. Further details can be obtained from the lead author. Drain management involved hourly checks of the amount and colour of CSF drained, exit site condition and the patients’ neurological condition. Redness, inflammation, oozing of blood and CSF leakage at the exit site were all documented. The post-operative dressing was changed at 24 h using 2 % chlorhexidine Clinell™ wipes to clean the site. Following this, the dressing was changed weekly or when soiled.

Routine sampling of CSF from an EVD was not advocated unless there was a specific clinical indication for fear of introducing contamination into the sterile closed circuit. Patients presenting with shunt infection or de novo ventriculitis requiring EVD insertion had CSF sampling daily. For all other cases, CSF sampling was performed on the day prior to removal of the EVD or as part of a septic screen should the child demonstrate clinical evidence of infection. All CSF samples were sent to the on-site microbiology department and processed immediately. A cell count was made up of the neat CSF and a gram stain performed on the spun deposit, for a differential white cell count and for the presence of organisms. Primary culture of the spun deposit was performed on blood and chocolate agar incubated for 40–48 h at 35–37 °C in 5–10 % CO₂, MacConkey agar incubated for 18–24 h in air at 37 °C, Sabouraud agar incubated for 5 days in air at 35–37 °C and blood agar incubated anaerobically for 5 days. Additional enrichment was performed by inoculation of brain-heart infusion for overnight enrichment at 35–37 °C followed by subculture on blood and chocolate incubated for 18–24 h.

EVD catheter tips were cultured by rolling the terminal 5 cm across a blood agar plate and incubating at 35–37 °C for 18–24 h.

Data collection

In this study, a LTEVD infection was defined as a novel bacterial growth or detection in the CSF and/or LTEVD catheter that had arisen during the period of the LTEVD being in situ and that resulted in a change in treatment (antibiotic therapy and/or change of EVD). When assessing suspected cases of LTEVD infection, systemic factors, white cell count in the CSF, bacterial growth on culture from CSF/LTEVD catheter samples and antibiotic treatment were all considered before coming to a conclusion as to whether a LTEVD infection was present. LTEVD CSF infection was considered to have occurred if there was growth on primary culture, growth on subculture only and organisms were seen, growth in repeated samples on subculture when no organisms had been seen or where organisms were seen on repeated gram stain without growth. Growth from the tip without growth in the CSF was not automatically graded as a LTEVD CSF infection. Each case was managed on an individual basis. The lead microbiology consultant for neurosurgery and the neurosurgeon took the final decision as to whether the LTEVD had been infected during the management of the case and that decision has been used in this review.

The following data were retrieved from the departmental operative database, operating theatre log and clinical record.

The total number of LTEVD procedures performed during the study period, the number of LTEVD infections, the duration of insertion and the rate of inadvertent LTEVD dislodgement were recorded. LTEVDs require a further surgical procedure under general anaesthetic for removal. It was noted whether the removal of the LTEVD was part of another surgical procedure (such as insertion of ventriculoperitoneal (VP) shunt) or whether the removal was performed in
isolation. Underlying diagnosis and patient age at the time of LTEVD insertion was also recorded.

Patients who required LTEVD insertion due to an existing infection were excluded from the data set when considering the final infection rate, due to possible treatment-induced discrepancies when testing for novel LTEVD infection.

When reporting the extra procedures needed for LTEVD removal, LTEVD insertions for the cohort with existing infection \( (n=48) \) were omitted, as these patients would have had a subsequent procedure to reinsert a shunt in theatre, irrespective of the type of EVD inserted.

A 2×2 Fisher’s exact test and Student’s t test were used for assessing a significant difference between the categorical data.

Results

One hundred seventy-seven patients had 181 LTEVDs placed between 2 January 2008 and 9 March 2012. The mean age of the patients was 6.6 years with a range of 0–15.5 years. Of the 181 procedures, 85 were inserted for intraventricular haemorrhage (47 %), 48 for infection (27 %), 13 for tumour-related hydrocephalus (7.2 %), 31 as a temporising measure (17 %) (where an EVD was inserted as an emergency measure and a definitive CSF diversion was performed subsequently) and 4 for trauma (2.2 %).

Of the 133 patients with no existing infection, microbiology analysis identified five cases of novel LTEVD infection, an infection rate of 3.8 %. No LTEVD infections were identified in the cohort \( (n=48) \) that required a LTEVD due to an existing infection. Out of the total 181 procedures, five novel cases of LTEVD infection were identified, an infection rate of 2.76 %. Three other bacterial growths were recorded but were explained by sample contamination (two cases) and existing surgical site infection (one case).

As can be seen in Table 1, there was no obvious trend for infection in younger or older patients, with LTEVDs from a wide range of age groups being infected. When comparing the ages of the infected and non-infected groups, statistical analysis showed no evidence for age as a risk factor for LTEVD infections \( (p=0.8967) \). Four of the five infected LTEVDs were inserted for longer than the median duration of insertion; however, there was no significant difference in LTEVD insertion duration between the infected \( (n=5) \) and non-infected \( (n=128) \) groups \( (p=0.1881) \). One of the infected cases was inserted immediately after an endoscopic procedure. Four out of the five infected LTEVD cases were caused by coagulase-negative staphylococci (CONS).

The mean duration of LTEVD insertion was 11.2 days (range 0 to 42 days and a median of 10 days, interquartile range of 19 days).

Four out of 181 (2.2 %) of the LTEVD procedures carried out during this time inadvertently dislodged, requiring an extra procedure to reinsert the EVD. No patients required EVD revision due to blockage. Thirteen extra procedures were carried out in theatre, specifically to remove the EVD, affecting 13/133 (9.8 %) of our patients (excluding the 48 LTEVDs inserted due to existing infection, as these would have an inevitable subsequent procedure to reinsert a non-infected shunt), where as the remainder of the removals were carried out during a subsequent procedure the patient required; thus, no extra procedures were needed to remove the EVD for these patients. The total number of extra operations required in this LTEVD cohort was thus 17 (9.4 %).

Discussion

A major complication of EVD insertion is CSF infection [2], posing a significant risk to patients as well as placing an additional burden on hospital resources. A range of infection rates from short-tunnelled EVDs has been reported, from 3.4 to 32.2 % [2–8, 12–20]. The data for infection rates of short-tunnelled EVDs are summarised in Fig. 1. This study, utilising LTEDV, reports a lower EVD infection rate when compared with previously published literature.

EVD infections: the risk factors

Numerous studies have attempted to identify factors contributing to EVD-related infection. CSF leakage particularly near the catheter exit site [21, 22], duration of EVD insertion [3, 12], EVD reinsertion [23], presence [24] or absence [25] of prophylactic antibiotics and CSF sampling [5] have all been suggested as significant contributing factors towards the onset of EVD-related infection. Other factors such as breaches of the closed system [12] and surgical protocol violation [22] and regular catheter change [26] have also been investigated. Comparing existing series is fraught with difficulty due to the varying age groups studied (adult and paediatric), differing underlying aetiology and lack of standardised protocols for the insertion and management of EVDs. Currently, therefore, there is little agreement about the relative significance of these contributing factors towards CSF infection in EVD patients. What seems clear is that EVD infection is unacceptably high in most reported series. This exclusively paediatric study of long-tunnelled EVD incorporating a predefined guideline for perioperative EVD management has revealed an infection rate of 3.8 %, a rate substantially less than that previously reported.

The evidence for tunnelling in reducing EVD infection

CSF leakage, either at the cranial site or the EVD exit site, is strongly correlated with infection risk. By increasing the
distance from the burr hole to the exit site, the resistance to
CSF flow around the outside of the catheter will be greater,
thus reducing CSF leakage. Clearly, the distance that bacteria
have to migrate in order to colonise the CSF compartment is
also greater. Omar and Haspani found that tunnelling only as
far as 5 cm from the burr hole was sufficient to reduce the
infection rate from 62.9 to 11.5 % [9]. For postero-parietal or
parieto-occipital burr holes in children, the options for
local
the anterior
abdominal wall or, less commonly, the anterior chest wall
(well away from the nipple or breast bud), resulting in a
tunnelling distance of at least 20 cm.

The results presented in this paper demonstrate comparable
results to the other two studies [27, 28] that have investigated
the effectiveness of LTEVDs. In the study by Khanna et al., a
0 % infection rate was achieved for the first 16 days after
LTEVD insertion and an overall infection rate of 4 %, in 100
adult and paediatric patients [27]. It was concluded that
LTEVDs had a low rate of infection and could remain in place
for up to 40 days. A more recent study [28], using a non-
antibiotic-impregnated LTEVD, in 114 adult and paediatric
patients requiring more than 7 days drainage, found the

| Data set number | Organism on culture                      | Age at insertion | Duration of insertion (days) | Reason for insertion                        |
|-----------------|------------------------------------------|------------------|------------------------------|---------------------------------------------|
| 145             | Coagulase-negative staphylococcus        | 5 years and 11 months | 7                           | A temporising measure (post endoscopic procedure) |
| 169             | Gram-positive cocci                      | 9 months         | 28                           | Intraventricular haemorrhage              |
| 51              | Coagulase-negative staphylococcus        | 15 years and 0 month | 23                          | Intraventricular haemorrhage           |
| 88              | Coagulase-negative staphylococcus        | 2 days           | 21                           | Temporising measure (spinal dysraphism)  |
| 79              | Coagulase-negative staphylococcus        | 15 years and 4 months | 12                          | Intraventricular haemorrhage           |

Fig. 1 A comparison of EVD infection rates across previous series, using either a subcutaneous long-tunnelled EVD or a short/non-tunnelled procedure
Infection rate to be 6.8 %, which was deemed comparable with the infection rate of standard short-tunnelled EVDS. Notably, LTEVDs were capable of remaining in place for long periods of time (up to 60 days, with a mean duration of 20 days) and no additional morbidity was associated with the LTEVD procedure.

Both of these studies indicate promise of the LTEVD technique though without conclusive evidence of their effectiveness in the paediatric population.

Further strengthening the LTEVD argument: experience from this single-centre study

Our study demonstrated a LTEVD infection rate of 3.8 % (five out of 133), which, as demonstrated by Fig. 1, compares favourably with previously published data on non-LTEVD series. A review of EVD infection [2], using data from 23 studies, comprising 5,733 EVD procedures in both adults and children, reported an infection rate of 8.8 %.

Our study demonstrated a LTEVD infection rate of 3.8 % (five out of 133), which, as demonstrated by Fig. 1, compares favourably with previously published data on non-LTEVD series. A review of EVD infection [2], using data from 23 studies, comprising 5,733 EVD procedures in both adults and children, reported an infection rate of 8.8 %.

The average duration of insertion was 11.2 days, with one LTEVD affords some protection against this complication.

Four out of 181 (2.2 %) LTEVDs in this study were inadvertently dislodged and required a separate procedure to reinsert the EVD. Data on the rate of displacement of EVD are sparse. In another study, using short-tunnelled EVDS and 3 publications using LTEVDs [27–29] with our series. A statistically significant difference (p<0.05) was found in the EVD-related infection rate between our study and 14 of the studies using the short-tunnelled procedure. Furthermore, there was no significant difference in the infection rates when comparing our study to the other three published studies using a long subcutaneous tunnel, suggesting that tunnelling seems to be a major contributing factor when considering EVD infection.

The infection rate reported does not include the 48 cases that required a LTEVD insertion for an existing infection as these patients may have been on active treatment for existing infection, which may affect the ability to detect a novel infection. Infection is a well-recognised complication of EVD insertion in patients with clean CSF before insertion. However, there is also a rate of novel infection, with new organisms, in the group where the EVD is placed as a part of the treatment for infection. There were no reported novel EVD infections in this group with an existing infection (n=48). Therefore, the total infection rate, including this group that require a LTEVD for infection, is 2.76 % (five out of 181).

Four out of 181 (2.2 %) LTEVDs in this study were inadvertently dislodged and required a separate procedure to reinsert the EVD. Data on the rate of displacement of EVD are sparse. In another study, using short-tunnelled EVD, a dislodgement rate of two out of 51 (8.1 %) was reported [11]. This would imply that the combination of a reservoir and LTEVD affords some protection against this complication. The average duration of insertion was 11.2 days, with one LTEVD remaining in place for 42 days. Our data and the data of the other LTEVD studies [27–29] suggest that LTEVDs can safely remain in place for long periods of time without the attendant risks of infection and dislodgement. It was noted that four of the five infected LTEVDs were inserted for longer than the median duration of insertion; however, a statistical comparison found no significant difference in the ages of the two groups. Duration of EVD insertion has been shown to be a significant risk factor when using short-tunnelled EVDS [2, 3], further strengthening the argument for a LTEVD protocol.

Additionally, one of the infected cases was inserted immediately after an endoscopic procedure, suggesting that this may have been a contributory factor to the LTEVD infection, which would concur with the previous literature where intraoperative endoscope use was considered to be an additional risk factor when considering shunt infection rates in the paediatric population [36].

The use of a LTEVD incorporating a reservoir will inevitably result in an extra surgical procedure (to remove the EVD) in some children. This study reported an extra procedure rate of 9.4 %. We would argue that the benefits of the long tunnel in terms of reducing infection rate and inadvertent dislodgement outweigh this inconvenience.

Antibiotic-impregnated catheters: their importance in reducing EVD infections

The importance of using an antibiotic-impregnated catheter (AIC) to lower infection rates in this cohort must not be underestimated. The Bactiseal™ catheters used for this cohort contained 0.15 % clindamycin and 0.054 % rifampicin. Several recent studies have demonstrated the effectiveness of using antibiotic-impregnated EVD catheters in both the adult and paediatric population. A recent systematic review and meta-analysis [37] identified several studies in both the adult and paediatric populations where antibiotic impregnation of the EVD catheter was beneficial in reducing EVD-related infections.

A six-centre randomised controlled trial in the adult population [38] has also shown a significant reduction in LTEVD infections, from 9.4 to 1.3 % when using minocycline- and rifampicin-impregnated catheters [38]. In a prospective versus historical cohort study of 91 paediatric patients, Tamburrini et al. [39] reported a significant reduction in EVD infection rates, from 31.8 to 2.1 % when using AICs in paediatric EVDS. In a further study, when AICs were inserted in a centre already using prophylactic, systemic antibiotic treatment, EVD infection rates were reduced from 23.5 to 4.3 % [40], further strengthening the argument for AIC use in EVDS.

When considering the antibiotics impregnated into the catheters, both minocycline/rifampin-impregnated ventricular catheter and clindamycin/rifampin-impregnated EVD catheter (used in this study) have been shown to be equally effective at reducing EVD-related infections [41].

However, not all of the data suggest that AICs have a beneficial impact in EVD insertion. A randomised controlled trial of 184 patients from another centre [42] showed that
AICs did not have a significantly higher rate of CSF infection (1 %) compared to catheters without antibiotic impregnation (3 %), and there was no significant difference of clinical outcome at 6 months. A more recent randomised controlled study also demonstrated similar findings in 348 adult patients, where AICs used in EVDs did not contribute to a reduction in infection rate; however, this could be attributed to a low baseline rate of infection and so difficult to prove an AIC-related reduction [43].

The risk of a false negative CSF culture when drawing CSF from an AIC must also be considered. Using an in vitro model, an increased risk of false negative results of infected CSF has been demonstrated [44]. Additionally, an increased rate of infection has been noted in paediatric VP shunt patients with prior EVD insertion using an AIC [45], the authors postulated that prior use of an AIC increased the potential for resistant organisms.

In summary, despite the possible risk of false negative CSF sampling and antibiotic resistance, there is a body of both level I and level II evidences, supporting the conclusion that AICs do reduce EVD infection rates.

The role of AICs used as a part of the treatment protocol for patients with pre-existing infection has been debated [46]. However, for the cohort requiring LTEVD insertion for pre-existing infection in this study (n=48), the AIC tubing was not employed as a specific treatment for the infection, for which appropriate intravenous and intraventricular antibiotics were administered before LTEVD insertion. Therefore, despite the licence for Bactiseal™ AIC catheters being for prevention of infection only, it was departmental practice to use AICs for all EVD insertions, whether infection was suspected at insertion or not.

The relative contribution of AICs, a long subcutaneous tunnel and a pre-defined protocol for perioperative management of the EVD is difficult to elucidate in this study. There is evidence from another study that a comprehensive EVD management protocol, similar to that implemented in this cohort, was effective in reducing EVD-related infection rates. Kubilay et al. cited a reduction in infection rate from 1.06 to 0 % in EVD procedures, over a 4-year period [47]. The effectiveness of protocols in reducing shunt infection has also been well demonstrated in the North American Shunt registry [48].

Implications and limitations

This low infection rate and low dislodgement rate shown for EVDs in this study, using a LTEVD, an AIC and a perioperative management protocol, represents a potential for both clinical and economic benefits. Fewer EVD infections would reduce the patient’s duration of hospital admission and reduce the risk from further surgery required to replace an infected EVD. A lower dislodgement rate is both safer for the patient and cost-effective, as there is a reduced risk and cost brought about by extra theatre time.

Our study does have some limitations. The multi-study comparison (Fig. 1) does not take into account the different operating protocols and infection definitions across the centres at which the procedures were carried out. As discussed, EVD-related infection is a multi-factorial problem [49] and it would be difficult to disregard all the compounding factors apart from the tunnelling length and the use of AICs that may influence the comparison with the other studies. This study was also conducted in the paediatric population, and comparing with adult studies may not offer a true comparison. Further studies may wish to assess the cost-effectiveness of this procedure, specifically in relation to hospital stay and extra operating time.

Conclusion

Long-tunnelled EVDs, using an antibiotic-impregnated catheter and managed according to an agreed perioperative management protocol, carry a lower infection rate and dislocation rate than the more widely used short-tunnelled procedure. We believe that the reduced morbidity and costs associated with such a policy outweigh the disadvantage of requiring an additional procedure for EVD removal.

Acknowledgments The authors thank Professor Hazel Inskip, MSc, PhD, FFPH, Southampton University, for her assistance on statistical analysis and Jody O’Connor, Clinical Nurse Specialist, Great Ormond Street Hospital, for the development of the Great Ormond Street EVD insertion protocol.

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. O’Neill BR, Velez DA, Braxton EE, Whiting D, Oh MY (2008) A survey of ventriculostomy and intracranial pressure monitor placement practices. Surg Neurol 70(3):268–273, Discussion 273
2. Lozier AP, Sciaccia RR, Romangnoli MF, Connelly ES Jr (2002) Ventriculostomy-related infection: a critical review of the literature. Neurosurgery 51:170–182
3. Arabi Y, Memish ZA, Balkhy HH, Francis C, Ferayan A, Al Shimemer A, Almuneef MA (2005) Ventriculostomy-associated infections: incidence and risk factors. Am J Infect Control 33(3):137–143
4. Aucoin PJ, Kotilainen HR, Gantz NM, Davidson R, Kellogg P, Stone B (1986) Intracranial pressure monitors. Epidemiologic study of risk factors and infections. Am J Med 80(3):369–376
5. Hader WJ, Steinbok P (2000) The value of routine cultures of the cerebrospinal fluid in patients with external ventricular drains. Neurosurgery 46(5):1149–1155
6. Öhrström JK, Skou JK, Ejlertsen T, Kosteljanetz M (1989) Infected ventriculostomy: bacteriology and treatment. Acta Neurochir 100(1–2):67–69
7. Pfister W, Muhlbauer M, Czech T, Reineprecht A (2003) Early diagnosis of external ventricular drainage infection: results of a prospective study. J Neurol Neurosurg Psychiatry 74:929–932
8. Stenager E, Gerner-Smidt P, Kock-Jensen C (1986) Ventriculostomy-related infections—an epidemiological study. Acta Neurochir (Wien) 83:20–23
9. Oscar MA, Haspasi MSM (2010) The risk factors of external ventricular drainage-related infection at Hospital Kuala Lumpur: an observational study. Malaysian J Med Sci 17(3):48–54
10. Sandalcioglu IE, Stolke D (2003) Failure of regular external ventricular drain exchange to reduce CSF infection. J Neurol Neurosurg Psychiatry 74:1598–1599
11. Berger A, Weninger M, Reineprecht A, Haschke N, Kohlhauser C, Pollak A (2000) Long-term experience with subcutaneously tunneled external ventricular drainage in infants. Child’s Nerv Syst 16:103–110
12. Mayhall CG, Archer NH, Lamb VA, Spadora AC, Baggett JW, Ward JD, Nanayan RK (1984) Ventriculostomy-related infections—a prospective epidemiologic study. N Engl J Med 310(9):553–559
13. Holloway KL, Barnes T, Choi S, Bullock R, Marshall LF, Eisenberg HM, Jane JA, Ward JD, Young HF, Marmarou A (1996) Ventriculostomy infections: the effect of monitoring duration and catheter exchange in 584 patients. J Neurol Neurosurg Psychiatry 65(3):419–424
14. Chan KH, Mann KS (1988) Prolonged therapeutic external ventriculostomy. Curr Opin Psychiatry 74:1598–1599
15. Friedman WA, Vries JK (1980) Percutaneous tunnel ventriculostomy. J Neurosurgery 31(5):898–903, Discussion 903–905
16. Chan KH, Mann KS (1988) Prolonged therapeutic external ventriculostomy: bacteriology and treatment. Acta Neurochir 100(1–2):79–84
17. Connolly ES, Yin MT (2013) Rates and determinants of antibiotic-coated external ventricular drains. Neurosurgery 63(3):E12–E20
18. Connolly ES, Yin MT (2013) Rates and determinants of antibiotic-coated external ventricular drains: a systematic review. Neurosurgery 68(4):996–1005, Jan 6
19. Sahni A, Zabramski JM, Whiting D, Darouiche RO, Horner TG, Olson J, Robertson C, Hamilton AJ (2003) Efficacy of antimicrobial-impregnated external ventricular drain catheters for the prevention of CSF shunt infections: a systematic review and meta-analysis. Br J Neurosurg 26(2):175–184
20. Robertson C, Hamilton AJ (2003) Efficacy of antimicrobial-impregnated external ventricular drain catheters: a prospective, randomized, controlled trial. J Neurosurg 98(4):725–730
21. Budgett S, Barlow S, DeBella D, Matalon S, Baguley B, Desai M, Nandedkar A, Young SL, Okonkwo DO, Albers GW, Berlina J, Connolly ES, Wang J, Zabramski JM (2013) Randomized controlled trial of antibiotic-impregnated external ventricular drains for prevention of infection. Neurosurgery 73(4):517–524, Discussion 524–525
22. Garwood JW, Jemal A, Sood A, Doherty J, Zabramski JM, Whiting D, Darouiche RO, Horner TG, Olson J, Robertson C, Hamilton AJ (2003) Efficacy of antimicrobial-impregnated external ventricular drain catheters for the prevention of CSF shunt infections: a systematic review and meta-analysis. Br J Neurosurg 20(2):191–198
23. Robertson C, Hamilton AJ, Albers GW, Berlina J, Connolly ES, Wang J, Zabramski JM (2013) Randomized controlled trial of antibiotic-impregnated external ventricular drains for prevention of infection. Neurosurgery 73(4):517–524, Discussion 524–525
24. Abla AA, Zabramski JM, Jahnke HK, Fusco D, Nakaji P (2011) Comparison of two antibiotic-impregnated ventricular catheters: a prospective sequential series trial. Neurosurgery 68(2):437–442
25. Abla AA, Zabramski JM, Jahnke HK, Fusco D, Nakaji P (2011) Comparison of two antibiotic-impregnated ventricular catheters: a prospective sequential series trial. Neurosurgery 68(2):437–442
26. Abla AA, Zabramski JM, Jahnke HK, Fusco D, Nakaji P (2011) Comparison of two antibiotic-impregnated ventricular catheters: a prospective sequential series trial. Neurosurgery 68(2):437–442
27. Abla AA, Zabramski JM, Jahnke HK, Fusco D, Nakaji P (2011) Comparison of two antibiotic-impregnated ventricular catheters: a prospective sequential series trial. Neurosurgery 68(2):437–442
28. Abla AA, Zabramski JM, Jahnke HK, Fusco D, Nakaji P (2011) Comparison of two antibiotic-impregnated ventricular catheters: a prospective sequential series trial. Neurosurgery 68(2):437–442
29. Abla AA, Zabramski JM, Jahnke HK, Fusco D, Nakaji P (2011) Comparison of two antibiotic-impregnated ventricular catheters: a prospective sequential series trial. Neurosurgery 68(2):437–442
30. Abla AA, Zabramski JM, Jahnke HK, Fusco D, Nakaji P (2011) Comparison of two antibiotic-impregnated ventricular catheters: a prospective sequential series trial. Neurosurgery 68(2):437–442
31. Abla AA, Zabramski JM, Jahnke HK, Fusco D, Nakaji P (2011) Comparison of two antibiotic-impregnated ventricular catheters: a prospective sequential series trial. Neurosurgery 68(2):437–442
32. Abla AA, Zabramski JM, Jahnke HK, Fusco D, Nakaji P (2011) Comparison of two antibiotic-impregnated ventricular catheters: a prospective sequential series trial. Neurosurgery 68(2):437–442
33. Abla AA, Zabramski JM, Jahnke HK, Fusco D, Nakaji P (2011) Comparison of two antibiotic-impregnated ventricular catheters: a prospective sequential series trial. Neurosurgery 68(2):437–442
34. Abla AA, Zabramski JM, Jahnke HK, Fusco D, Nakaji P (2011) Comparison of two antibiotic-impregnated ventricular catheters: a prospective sequential series trial. Neurosurgery 68(2):437–442
35. Abla AA, Zabramski JM, Jahnke HK, Fusco D, Nakaji P (2011) Comparison of two antibiotic-impregnated ventricular catheters: a prospective sequential series trial. Neurosurgery 68(2):437–442
36. Abla AA, Zabramski JM, Jahnke HK, Fusco D, Nakaji P (2011) Comparison of two antibiotic-impregnated ventricular catheters: a prospective sequential series trial. Neurosurgery 68(2):437–442
37. Abla AA, Zabramski JM, Jahnke HK, Fusco D, Nakaji P (2011) Comparison of two antibiotic-impregnated ventricular catheters: a prospective sequential series trial. Neurosurgery 68(2):437–442
38. Abla AA, Zabramski JM, Jahnke HK, Fusco D, Nakaji P (2011) Comparison of two antibiotic-impregnated ventricular catheters: a prospective sequential series trial. Neurosurgery 68(2):437–442
39. Abla AA, Zabramski JM, Jahnke HK, Fusco D, Nakaji P (2011) Comparison of two antibiotic-impregnated ventricular catheters: a prospective sequential series trial. Neurosurgery 68(2):437–442
40. Abla AA, Zabramski JM, Jahnke HK, Fusco D, Nakaji P (2011) Comparison of two antibiotic-impregnated ventricular catheters: a prospective sequential series trial. Neurosurgery 68(2):437–442
41. Abla AA, Zabramski JM, Jahnke HK, Fusco D, Nakaji P (2011) Comparison of two antibiotic-impregnated ventricular catheters: a prospective sequential series trial. Neurosurgery 68(2):437–442
42. Abla AA, Zabramski JM, Jahnke HK, Fusco D, Nakaji P (2011) Comparison of two antibiotic-impregnated ventricular catheters: a prospective sequential series trial. Neurosurgery 68(2):437–442
43. Abla AA, Zabramski JM, Jahnke HK, Fusco D, Nakaji P (2011) Comparison of two antibiotic-impregnated ventricular catheters: a prospective sequential series trial. Neurosurgery 68(2):437–442
44. Abla AA, Zabramski JM, Jahnke HK, Fusco D, Nakaji P (2011) Comparison of two antibiotic-impregnated ventricular catheters: a prospective sequential series trial. Neurosurgery 68(2):437–442
45. Abla AA, Zabramski JM, Jahnke HK, Fusco D, Nakaji P (2011) Comparison of two antibiotic-impregnated ventricular catheters: a prospective sequential series trial. Neurosurgery 68(2):437–442
46. Abla AA, Zabramski JM, Jahnke HK, Fusco D, Nakaji P (2011) Comparison of two antibiotic-impregnated ventricular catheters: a prospective sequential series trial. Neurosurgery 68(2):437–442
42. Wong GK, Ip M, Poon WS, Mak CW, Ng RY (2010) Antibiotics-impregnated ventricular catheter versus systemic antibiotics for prevention of nosocomial CSF and non-CSF infections: a prospective randomised clinical trial. J Neurol Neurosurg Psychiatry 81(10):1064–1067
43. Pople I, Poon W, Assaker R, Mathieu D, Iantosca M, Wang E, Zhang LW, Leung G, Chumas P, Menei P, Beydon L, Hamilton M, Kamaly I, Lewis S, Ning W, Megerian JT, McGirt MJ, Murphy JA, Michael A, Meling T (2012) Comparison of infection rate with the use of antibiotic-impregnated vs standard extraventricular drainage devices: a prospective, randomized controlled trial. Neurosurgery 71(1):6–13
44. Stevens EA, Palavecino E, Sherertz RJ, Shihabi Z, Couture DE (2010) Effects of antibiotic-impregnated external ventricular drains on bacterial culture results: an in vitro analysis: laboratory investigation. J Neurosurg 113(1):86–92
45. Hayhurst C, Cooke R, Williams D, Kandasamy J, O’Brien DF, Mallucci CL (2008) The impact of antibiotic-impregnated catheters on shunt infection in children and neonates. Childs Nerv Syst 24(5):557–562
46. Soleman J, Marbacher S, Fandino J, Fathi AR (2012) Is the use of antibiotic-impregnated external ventricular drainage beneficial in the management of iatrogenic ventriculitis? Acta Neurochir 154(1):161–164
47. Kubilay Z, Amini S, Fauerbach LL, Archibald L, Friedman WA, Layon AJ (2013) Decreasing ventricular infections through the use of a ventriculostomy placement bundle: experience at a single institution: clinical article. J Neurosurg 118(3):514–520
48. Kestle JR, Riva-Cambrin J, Wellons JC III, Kulkarni AV, Whitehead WE, Walker ML, Oakes J, Drake JM, Luerssen TG, Simon TD, Holubkov R (2011) A standardized protocol to reduce cerebrospinal fluid shunt infection: the hydrocephalus clinical research network quality improvement initiative. J Neurosurg Pediatr 8(1):22
49. Babu MA, Patel R, Marsh WR, Wijdicks EF (2012) Strategies to decrease the risk of ventricular catheter infections: a review of the evidence. Neurocrit Care 16(1):194–202